Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
ACST Acasti Pharma Inc
STBX Starbox Group Holdings Ltd
ANCFX American Funds Fundamental Investors® Class A
DFS Discover Financial Services
EJH E-Home Household Service Holdings Ltd
PYXS Pyxis Oncology Inc
FLGC Flora Growth Corp
BAOS Baosheng Media Group Holdings Ltd
CETY Clean Energy Technologies Inc
Go

Health Care : Biotechnology | Mid Cap Growth

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Price: Delayed
$70.54

Day's Change: -1.72 (-2.38%)

Bid: --

Ask: --

B/A Size: --

Day's High: 71.74

Day's Low: 67.83

Volume (Heavy Day) Today's volume of 2,428,350 shares is on pace to be much greater than INCY's 10-day average volume of 1,551,945 shares.: 2,428,350

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.